Amicus Therapeutics (NASDAQ:FOLD)

2:45 PM - 3:00 PM, Tuesday, June 4, 2019 ・ Theater 1
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, Amicus Therapeutics is committed to changing the lives of people with these life-threatening conditions.
Ticker:
FOLD
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2002
Main Therapeutic Focus:
Lead Product in Development:
Galafold
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
N/A